Novo Nordisk Reports Greater Weight Loss in Early Responders Treated with Higher-dose Wegovy
Idag, 08:28
02:28 AM EDT, 05/12/2026 (MT Newswires) -- Danish drugmaker Novo Nordisk (NOVO-B.CO) said Tuesday that a higher dose of Wegovy, or semaglutide, proved to be "highly effective"for weight loss in obese individuals during the Step Up clinical trial.
The randomized, double-blinded, parallel-group, and placebo-controlled trial evaluated the efficacy and safety of 7.2 milligrams of semaglutide against a 2.4 mg dose and placebo in 1,407 adults without type 2 diabetes.
A new sub-analysis showed that participants receiving the higher dose achieved an average weight loss of 27.7% at week 72, with results indicating a faster rate of weight loss compared with the lower dose.
Separately, a secondary analysis involving a sub-population of 55 participants found that 84% of the lost weight with semaglutide came from a reduction in fat mass, reflecting improved muscle health.
Ämnen i artikeln
Novo Nordisk Reports Greater Weight Loss in Early Responders Treated with Higher-dose Wegovy
Idag, 08:28
02:28 AM EDT, 05/12/2026 (MT Newswires) -- Danish drugmaker Novo Nordisk (NOVO-B.CO) said Tuesday that a higher dose of Wegovy, or semaglutide, proved to be "highly effective"for weight loss in obese individuals during the Step Up clinical trial.
The randomized, double-blinded, parallel-group, and placebo-controlled trial evaluated the efficacy and safety of 7.2 milligrams of semaglutide against a 2.4 mg dose and placebo in 1,407 adults without type 2 diabetes.
A new sub-analysis showed that participants receiving the higher dose achieved an average weight loss of 27.7% at week 72, with results indicating a faster rate of weight loss compared with the lower dose.
Separately, a secondary analysis involving a sub-population of 55 participants found that 84% of the lost weight with semaglutide came from a reduction in fat mass, reflecting improved muscle health.
Ämnen i artikeln
Analys
